Vycor Medical, Inc. (VYCO) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Vycor Medical, Inc. (VYCO) trades at $0.068 with AI Score 44/100 (Grade C). Vycor Medical, Inc. specializes in neurological medical devices and therapies, operating through its Vycor Medical and NovaVision segments. Market cap: $2.27M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for VYCO: VYCO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VYCO against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
VYCO: 1/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Vycor Medical, Inc. (VYCO) Healthcare & Pipeline Overview
Vycor Medical, Inc. develops and markets neurological medical devices, including the ViewSite Brain Access System, and non-invasive vision rehabilitation therapies. Operating in the U.S. and Europe, the company targets hospitals and medical professionals with its specialized offerings in neurosurgery and vision impairment solutions, facing competition in the broader medical device market.
What Is the Investment Thesis for VYCO?
Vycor Medical, Inc. presents a focused investment opportunity within the neurological medical device sector. The company's gross margin of 85.3% indicates strong pricing power and efficient cost management in its core product lines. Growth catalysts include expanding the market reach of the ViewSite Brain Access System and further penetration of NovaVision therapies in Europe via the HelferApp GmbH partnership. However, the company's negative P/E ratio of -191.81 and negative profit margin of -0.9% highlight profitability challenges. The company's small size, with only 7 employees, also introduces operational risks. Investors should closely monitor revenue growth and cost management initiatives to assess the company's path to profitability.
Based on FMP financials and quantitative analysis
VYCO Key Highlights
Gross Margin of 85.3% indicates strong pricing power in its niche market.
- Operates in two segments: Vycor Medical (neurosurgical devices) and NovaVision (vision rehabilitation therapies).
- Partnership with HelferApp GmbH expands NovaVision's reach into Austria and Switzerland.
- Market capitalization of $2.27M reflects its small size and potential for high volatility.
- Negative P/E ratio of -191.81 signals current unprofitability.
Who Are VYCO's Competitors?
VYCO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CMPD CompuMed, Inc. | $7.86 | +16.44% | $10.1M | 60 |
| HLYK HealthLynked Corp. | $2.50 | -3.85% | $7.35M | 46 |
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PLSM PLSM | $3.01 | +4.88% | $19.6M | 60 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.27 | -1.08% | $24.6M | 73 |
| RDGL Vivos Inc. | $0.05 | -5.33% | $26.5M | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VYCO's Key Strengths?
High gross margin (85.3%)
- Specialized product offerings in neurosurgery and vision rehabilitation
- Partnership for European market access
- Proprietary technology in VBAS
What Are VYCO's Weaknesses?
Small market capitalization ($0.00B)
- Negative P/E ratio (-191.81) and profit margin (-0.9%)
- Small number of employees (7)
- Dependence on a limited number of products
What Could Drive VYCO Stock Higher?
Expansion of VBAS sales in the US and Europe.
- Growth of NovaVision therapies through the HelferApp GmbH partnership.
- Potential new product launches in neurosurgery (timeline: 2-3 years).
- Strategic partnerships with hospitals and medical centers.
- Expansion of telehealth delivery for NovaVision therapies (timeline: 1-2 years).
What Are the Key Risks for VYCO?
Competition from larger medical device companies with greater resources.
- Regulatory changes in the medical device industry affecting product approvals and compliance.
- Product liability risks associated with medical devices.
- Economic downturn affecting hospital budgets and capital spending.
- Risks associated with trading on the OTC Other market, including limited liquidity and disclosure.
What Are the Growth Opportunities for VYCO?
- Expansion of ViewSite Brain Access System (VBAS): The market for minimally invasive neurosurgical devices is growing due to the benefits of reduced trauma and faster recovery times. Vycor Medical can expand VBAS sales by targeting more hospitals and neurosurgeons in the US and Europe. Timeline: Ongoing.
- NovaVision Therapy Growth in Europe: The partnership with HelferApp GmbH provides a platform for expanding NovaVision therapies in Austria and Switzerland. The market for vision rehabilitation is driven by the increasing prevalence of stroke and brain injuries. By leveraging HelferApp's existing network and expertise, Vycor can accelerate the adoption of NovaVision therapies in these regions. Market size: Vision rehabilitation market in Europe is estimated to be substantial. Timeline: Ongoing.
- New Product Development in Neurosurgery: Vycor Medical can invest in developing new neurosurgical devices to complement the VBAS system. This could include instruments for tumor resection, aneurysm clipping, or spinal surgery. By expanding its product portfolio, Vycor can offer a more comprehensive solution to neurosurgeons and increase its revenue per customer. Market size: The global neurosurgery market is substantial. Timeline: 2-3 years.
- Strategic Partnerships with Hospitals: Establishing strategic partnerships with leading hospitals and medical centers can provide Vycor Medical with access to key opinion leaders and clinical trial opportunities. These partnerships can also facilitate the adoption of Vycor's products and therapies by providing training and support to medical professionals. Market size: Varies depending on the specific partnership. Timeline: Ongoing.
- Telehealth Expansion for NovaVision: Expanding the telehealth delivery of NovaVision therapies can increase accessibility and convenience for patients. This can be achieved by developing a user-friendly online platform that allows patients to receive therapy remotely. The telehealth market is growing rapidly, driven by technological advancements and increasing demand for remote healthcare services. Market size: Telehealth market is expanding rapidly. Timeline: 1-2 years.
What Are VYCO's Competitive Advantages?
- Specialized product offerings in niche markets (neurosurgery and vision rehabilitation).
- Proprietary technology in the ViewSite Brain Access System.
- Established relationships with hospitals and medical professionals.
- Partnership with HelferApp GmbH for European market access.
What Does VYCO Do?
Vycor Medical, Inc., established in 2005 and headquartered in Boca Raton, Florida, focuses on designing, developing, and marketing neurological medical devices and therapies. The company operates through two primary segments: Vycor Medical and NovaVision. The Vycor Medical segment offers the ViewSite Brain Access System (VBAS), a retraction and access system used in brain and spine surgeries, providing surgeons with enhanced visualization and access during delicate procedures. The NovaVision segment provides non-invasive, computer-based rehabilitation therapies aimed at individuals with vision impairments resulting from stroke or other brain injuries. These therapies are designed to help patients recover and improve their visual function. Vycor Medical has a licensing agreement with HelferApp GmbH, granting them the rights to provide NovaVision products and therapies in Austria and Switzerland. Vycor Medical, Inc. primarily serves hospitals and medical professionals across the United States and Europe. The company is a subsidiary of Fountainhead Capital Management Limited. Vycor Medical's focus on specialized neurological solutions positions it within a niche market, requiring continuous innovation and adaptation to evolving medical practices.
What Products and Services Does VYCO Offer?
- Designs and develops neurological medical devices.
- Markets devices for neurosurgery, including the ViewSite Brain Access System.
- Offers non-invasive computer-based vision rehabilitation therapies.
- Provides solutions for vision impairment resulting from stroke or brain injury.
- Serves hospitals and medical professionals in the United States and Europe.
- Licenses NovaVision products and therapies through partnerships.
How Does VYCO Make Money?
- Direct sales of medical devices to hospitals and medical professionals.
- Licensing agreements for distribution of NovaVision therapies.
- Revenue from vision rehabilitation therapy programs.
- Potential for recurring revenue through software subscriptions or maintenance contracts.
What Industry Does VYCO Operate In?
Vycor Medical, Inc. operates within the medical device industry, specifically targeting the neurological and vision rehabilitation sectors. The global medical device market is characterized by technological advancements, stringent regulatory requirements, and increasing demand for minimally invasive procedures. Competition includes both large, diversified medical device companies and smaller, specialized firms. Vycor Medical's focus on niche areas like brain access systems and vision rehabilitation allows it to differentiate itself, but it also faces challenges in scaling its operations and competing with larger players who have greater resources and broader market reach.
Who Are VYCO's Key Customers?
- Hospitals
- Medical professionals (neurosurgeons, ophthalmologists, rehabilitation specialists)
- Patients with vision impairments due to stroke or brain injury
How Vycor Medical, Inc. Is Valued
Vycor Medical, Inc. carries a market capitalization of $2.27M, placing it in the micro-cap category. Relative to its peer group, VYCO's quantitative score of 44/100 is below the peer average of 60/100.
Company Profile
Vycor Medical, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Boca Raton, US. The company is led by CEO Peter C. Zachariou. VYCO has traded publicly since 2013.
Key Financial Metrics
Return on equity for Vycor Medical, Inc. stands at 1.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -7.4%, showing how much profit it generates from its asset base. Its free cash flow yield is 3.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.13 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -3.6%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Vycor Medical, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
VYCO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- High gross margin (85.3%)
- Specialized product offerings in neurosurgery and vision rehabilitation
- Partnership for European market access
- Proprietary technology in VBAS
Bear Case
- Small market capitalization ($0.00B)
- Negative P/E ratio (-191.81) and profit margin (-0.9%)
- Small number of employees (7)
- Dependence on a limited number of products
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
VYCO Latest News
No recent news available for VYCO.
VYCO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VYCO.
Price Targets
Wall Street price target analysis for VYCO.
VYCO MoonshotScore
What does this score mean?
The MoonshotScore rates VYCO 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Peter C. Zachariou
Unknown
Information on Peter C. Zachariou's background is not available in the provided data. His career history, education, and previous roles are unknown. Further research would be needed to provide a comprehensive profile.
Track Record: Information on Peter C. Zachariou's track record is not available in the provided data. Key achievements, strategic decisions, and company milestones under his leadership are unknown. Further research would be needed to provide a comprehensive assessment.
VYCO OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Vycor Medical, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be required to provide regular financial disclosures, leading to increased information asymmetry and potential risks for investors. Investing in OTC Other stocks requires a higher degree of due diligence and risk tolerance compared to stocks listed on major exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry.
- Low trading volume and wide bid-ask spreads can lead to price volatility.
- Higher potential for fraud or manipulation compared to listed exchanges.
- OTC Other companies may have difficulty raising capital.
- Delisting risk if the company fails to meet minimum requirements.
- Verify the company's legal status and registration.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Check for any regulatory actions or legal disputes.
- Monitor trading volume and price activity.
- Understand the risks associated with OTC Other stocks.
- Company has been in operation for a significant period (incorporated in 2005).
- Operates in a regulated industry (medical devices).
- Has partnerships with other companies (HelferApp GmbH).
- Has a physical headquarters (Boca Raton, Florida).
- Subsidiary of Fountainhead Capital Management Limited.
Vycor Medical, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for VYCO?
VYCO holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Vycor Medical, Inc. specializes in neurological medical devices and therapies, operating through its Vycor Medical and NovaVision segments. The company's products serve hospitals and medical …
What does Vycor Medical, Inc. do?
Vycor Medical, Inc. is a medical device company that designs, develops, and markets neurological medical devices and therapies. It operates through two segments: Vycor Medical, which provides the ViewSite Brain Access System (VBAS) for neurosurgery, and NovaVision, which offers non-invasive vision rehabilitation therapies. The company primarily serves hospitals and medical professionals in the United States and Europe, offering specialized solutions for neurosurgical procedures and vision impairment resulting from brain injuries.
What are the main risks for VYCO?
Vycor Medical faces several risks, including competition from larger medical device companies, regulatory changes in the medical device industry, and potential product liability claims. As an OTC-listed company, VYCO is also subject to risks associated with limited liquidity, disclosure, and potential for manipulation. The company's small size and negative profitability further amplify these risks. Investors should carefully evaluate these factors before investing in VYCO.
What are the key factors to evaluate for VYCO?
Vycor Medical, Inc. (VYCO) holds an AI score of 44/100 (low). presents a focused investment opportunity within the neurological medical device sector. Not financial advice.
How frequently does VYCO data refresh on this page?
VYCO's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven VYCO's recent stock price performance?
Vycor Medical, Inc. (VYCO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: High gross margin (85.3%). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VYCO overvalued or undervalued right now?
Vycor Medical, Inc. (VYCO) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research VYCO before investing?
Before investing in Vycor Medical, Inc. (VYCO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding VYCO to a portfolio?
Key strength of Vycor Medical, Inc. (VYCO): High gross margin (85.3%). Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO's background and track record.
- AI analysis is pending, which could provide additional insights.
- OTC Other stocks carry higher risks than exchange-listed stocks.